| pubmed-article:8988665 | pubmed:abstractText | Regardless of surgical effectiveness, ongoing activity in parathyroid localization in hyperparathyroidism (HPT) is an established enterprise. Sestamibi (MIBI), the most recent new modality, is being assessed in this regard. | lld:pubmed |
